Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
Identifieur interne : 000318 ( Pmc/Curation ); précédent : 000317; suivant : 000319Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
Auteurs : H K Genant [États-Unis] ; C G Peterfy [États-Unis] ; R. Westhovens [Belgique] ; J-C Becker [États-Unis] ; R. Aranda [États-Unis] ; G. Vratsanos [États-Unis] ; J. Teng [États-Unis] ; J M Kremer [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2007.
Abstract
Assess the effect of abatacept on progression of structural damage over 2 years in patients with rheumatoid arthritis who had an inadequate response to methotrexate.
539 patients entered an open-label extension of the AIM (
In patients treated with abatacept for 2 years, greater reduction in progression of structural damage was observed in year 2 than in year 1. The mean change in total Genant-modified Sharp scores was reduced from 1.07 units in year 1 to 0.46 units in year 2. Similar reductions were observed in erosion and joint space narrowing scores. Following 2 years of treatment with abatacept, 50% of patients had no progression of structural damage as defined by a change in the total score of ⩽0 compared with baseline. 56% of patients treated with abatacept had no progression during the first year compared with 45% of patients treated with placebo. In their second year of treatment with abatacept, more patients had no progression than in the first year (66% vs 56%).
Abatacept has a sustained effect that inhibits progression of structural damage. Furthermore, the mean change in radiographic progression in patients treated with abatacept for 2 years was significantly lower in year 2 versus year 1, suggesting that abatacept may have an increasing disease-modifying effect on structural damage over time.
Url:
DOI: 10.1136/ard.2007.085084
PubMed: 18086727
PubMed Central: 2569144
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000318
Links to Exploration step
PMC:2569144Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial</title><author><name sortKey="Genant, H K" sort="Genant, H K" uniqKey="Genant H" first="H K" last="Genant">H K Genant</name><affiliation wicri:level="1"><nlm:aff id="aff1"><addr-line>University of California, San Francisco, San Francisco, California, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California, San Francisco, San Francisco, California</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><addr-line>Synarc, Inc., San Francisco, California, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Synarc, Inc., San Francisco, California</wicri:regionArea></affiliation></author><author><name sortKey="Peterfy, C G" sort="Peterfy, C G" uniqKey="Peterfy C" first="C G" last="Peterfy">C G Peterfy</name><affiliation wicri:level="1"><nlm:aff id="aff2"><addr-line>Synarc, Inc., San Francisco, California, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Synarc, Inc., San Francisco, California</wicri:regionArea></affiliation></author><author><name sortKey="Westhovens, R" sort="Westhovens, R" uniqKey="Westhovens R" first="R" last="Westhovens">R. Westhovens</name><affiliation wicri:level="1"><nlm:aff id="aff3"><addr-line>UZ Gasthuisberg, Leuven, Belgium</addr-line></nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>UZ Gasthuisberg, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Becker, J C" sort="Becker, J C" uniqKey="Becker J" first="J-C" last="Becker">J-C Becker</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Aranda, R" sort="Aranda, R" uniqKey="Aranda R" first="R" last="Aranda">R. Aranda</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Vratsanos, G" sort="Vratsanos, G" uniqKey="Vratsanos G" first="G" last="Vratsanos">G. Vratsanos</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Teng, J" sort="Teng, J" uniqKey="Teng J" first="J" last="Teng">J. Teng</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Kremer, J M" sort="Kremer, J M" uniqKey="Kremer J" first="J M" last="Kremer">J M Kremer</name><affiliation wicri:level="1"><nlm:aff id="aff5"><addr-line>Albany Medical College and The Center for Rheumatology, Albany, New York, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany Medical College and The Center for Rheumatology, Albany, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18086727</idno><idno type="pmc">2569144</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569144</idno><idno type="RBID">PMC:2569144</idno><idno type="doi">10.1136/ard.2007.085084</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">000318</idno><idno type="wicri:Area/Pmc/Curation">000318</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial</title><author><name sortKey="Genant, H K" sort="Genant, H K" uniqKey="Genant H" first="H K" last="Genant">H K Genant</name><affiliation wicri:level="1"><nlm:aff id="aff1"><addr-line>University of California, San Francisco, San Francisco, California, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California, San Francisco, San Francisco, California</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><addr-line>Synarc, Inc., San Francisco, California, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Synarc, Inc., San Francisco, California</wicri:regionArea></affiliation></author><author><name sortKey="Peterfy, C G" sort="Peterfy, C G" uniqKey="Peterfy C" first="C G" last="Peterfy">C G Peterfy</name><affiliation wicri:level="1"><nlm:aff id="aff2"><addr-line>Synarc, Inc., San Francisco, California, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Synarc, Inc., San Francisco, California</wicri:regionArea></affiliation></author><author><name sortKey="Westhovens, R" sort="Westhovens, R" uniqKey="Westhovens R" first="R" last="Westhovens">R. Westhovens</name><affiliation wicri:level="1"><nlm:aff id="aff3"><addr-line>UZ Gasthuisberg, Leuven, Belgium</addr-line></nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>UZ Gasthuisberg, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Becker, J C" sort="Becker, J C" uniqKey="Becker J" first="J-C" last="Becker">J-C Becker</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Aranda, R" sort="Aranda, R" uniqKey="Aranda R" first="R" last="Aranda">R. Aranda</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Vratsanos, G" sort="Vratsanos, G" uniqKey="Vratsanos G" first="G" last="Vratsanos">G. Vratsanos</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Teng, J" sort="Teng, J" uniqKey="Teng J" first="J" last="Teng">J. Teng</name><affiliation wicri:level="1"><nlm:aff id="aff4"><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Kremer, J M" sort="Kremer, J M" uniqKey="Kremer J" first="J M" last="Kremer">J M Kremer</name><affiliation wicri:level="1"><nlm:aff id="aff5"><addr-line>Albany Medical College and The Center for Rheumatology, Albany, New York, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany Medical College and The Center for Rheumatology, Albany, New York</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of the Rheumatic Diseases</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective:</title><p>Assess the effect of abatacept on progression of structural damage over 2 years in patients with rheumatoid arthritis who had an inadequate response to methotrexate.</p></sec><sec><title>Methods:</title><p>539 patients entered an open-label extension of the AIM (<underline>A</underline>batacept in <underline>I</underline>nadequate responders to <underline>M</underline>ethotrexate) trial and received abatacept. Radiographic assessment of the hands and feet was performed at baseline, year 1 and year 2. At year 2, each patient’s radiographs were scored for progression blinded to sequence and treatment allocation.</p></sec><sec><title>Results:</title><p>In patients treated with abatacept for 2 years, greater reduction in progression of structural damage was observed in year 2 than in year 1. The mean change in total Genant-modified Sharp scores was reduced from 1.07 units in year 1 to 0.46 units in year 2. Similar reductions were observed in erosion and joint space narrowing scores. Following 2 years of treatment with abatacept, 50% of patients had no progression of structural damage as defined by a change in the total score of ⩽0 compared with baseline. 56% of patients treated with abatacept had no progression during the first year compared with 45% of patients treated with placebo. In their second year of treatment with abatacept, more patients had no progression than in the first year (66% vs 56%).</p></sec><sec><title>Conclusions:</title><p>Abatacept has a sustained effect that inhibits progression of structural damage. Furthermore, the mean change in radiographic progression in patients treated with abatacept for 2 years was significantly lower in year 2 versus year 1, suggesting that abatacept may have an increasing disease-modifying effect on structural damage over time.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Choy, Eh" uniqKey="Choy E">EH Choy</name></author><author><name sortKey="Panayi, Gs" uniqKey="Panayi G">GS Panayi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goronzy, Jj" uniqKey="Goronzy J">JJ Goronzy</name></author><author><name sortKey="Weyand, Cm" uniqKey="Weyand C">CM Weyand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moreland, Lw" uniqKey="Moreland L">LW Moreland</name></author><author><name sortKey="Alten, R" uniqKey="Alten R">R Alten</name></author><author><name sortKey="Van Den Bosch, F" uniqKey="Van Den Bosch F">F Van den Bosch</name></author><author><name sortKey="Appelboom, T" uniqKey="Appelboom T">T Appelboom</name></author><author><name sortKey="Leon, M" uniqKey="Leon M">M Leon</name></author><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Becker, Jc" uniqKey="Becker J">JC Becker</name></author><author><name sortKey="Schiff, M" uniqKey="Schiff M">M Schiff</name></author><author><name sortKey="Luggen, M" uniqKey="Luggen M">M Luggen</name></author><author><name sortKey="Sherrer, Y" uniqKey="Sherrer Y">Y Sherrer</name></author><author><name sortKey="Kremer, J" uniqKey="Kremer J">J Kremer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kremer, Jm" uniqKey="Kremer J">JM Kremer</name></author><author><name sortKey="Genant, Hk" uniqKey="Genant H">HK Genant</name></author><author><name sortKey="Moreland, Lw" uniqKey="Moreland L">LW Moreland</name></author><author><name sortKey="Russell, As" uniqKey="Russell A">AS Russell</name></author><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author><author><name sortKey="Abud Mendoza, C" uniqKey="Abud Mendoza C">C Abud-Mendoza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kremer, Jm" uniqKey="Kremer J">JM Kremer</name></author><author><name sortKey="Westhovens, R" uniqKey="Westhovens R">R Westhovens</name></author><author><name sortKey="Leon, M" uniqKey="Leon M">M Leon</name></author><author><name sortKey="Di Giorgio, E" uniqKey="Di Giorgio E">E Di Giorgio</name></author><author><name sortKey="Alten, R" uniqKey="Alten R">R Alten</name></author><author><name sortKey="Steinfeld, S" uniqKey="Steinfeld S">S Steinfeld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scott, Dl" uniqKey="Scott D">DL Scott</name></author><author><name sortKey="Pugner, K" uniqKey="Pugner K">K Pugner</name></author><author><name sortKey="Kaarela, K" uniqKey="Kaarela K">K Kaarela</name></author><author><name sortKey="Doyle, Dv" uniqKey="Doyle D">DV Doyle</name></author><author><name sortKey="Woolf, A" uniqKey="Woolf A">A Woolf</name></author><author><name sortKey="Holmes, J" uniqKey="Holmes J">J Holmes</name></author><author><name sortKey="Hieke, K" uniqKey="Hieke K">K Hieke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Welsing, Pm" uniqKey="Welsing P">PM Welsing</name></author><author><name sortKey="Van Gestel, Am" uniqKey="Van Gestel A">AM van Gestel</name></author><author><name sortKey="Swinkels, Hl" uniqKey="Swinkels H">HL Swinkels</name></author><author><name sortKey="Kiemeney, La" uniqKey="Kiemeney L">LA Kiemeney</name></author><author><name sortKey="Van Riel, Pl" uniqKey="Van Riel P">PL van Riel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arnett, Fc" uniqKey="Arnett F">FC Arnett</name></author><author><name sortKey="Edworthy, Sm" uniqKey="Edworthy S">SM Edworthy</name></author><author><name sortKey="Bloch, Da" uniqKey="Bloch D">DA Bloch</name></author><author><name sortKey="Mcshane, Dj" uniqKey="Mcshane D">DJ McShane</name></author><author><name sortKey="Fries, Jf" uniqKey="Fries J">JF Fries</name></author><author><name sortKey="Cooper, Ns" uniqKey="Cooper N">NS Cooper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peterfy, C" uniqKey="Peterfy C">C Peterfy</name></author><author><name sortKey="Miaux, Y" uniqKey="Miaux Y">Y Miaux</name></author><author><name sortKey="Wu, C" uniqKey="Wu C">C Wu</name></author><author><name sortKey="Jiang, Y" uniqKey="Jiang Y">Y Jiang</name></author><author><name sortKey="Sieffert, M" uniqKey="Sieffert M">M Sieffert</name></author><author><name sortKey="Mokliatchouk, O" uniqKey="Mokliatchouk O">O Mokliatchouk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genant, Hk" uniqKey="Genant H">HK Genant</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genant, Hk" uniqKey="Genant H">HK Genant</name></author><author><name sortKey="Jiang, Y" uniqKey="Jiang Y">Y Jiang</name></author><author><name sortKey="Peterfy, C" uniqKey="Peterfy C">C Peterfy</name></author><author><name sortKey="Lu, Y" uniqKey="Lu Y">Y Lu</name></author><author><name sortKey="Redei, J" uniqKey="Redei J">J Redei</name></author><author><name sortKey="Countryman, Pj" uniqKey="Countryman P">PJ Countryman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lassere, M" uniqKey="Lassere M">M Lassere</name></author><author><name sortKey="Boers, M" uniqKey="Boers M">M Boers</name></author><author><name sortKey="Van Der Heijde, D" uniqKey="Van Der Heijde D">D van der Heijde</name></author><author><name sortKey="Boonen, A" uniqKey="Boonen A">A Boonen</name></author><author><name sortKey="Edmonds, J" uniqKey="Edmonds J">J Edmonds</name></author><author><name sortKey="Saudan, A" uniqKey="Saudan A">A Saudan</name></author><author><name sortKey="Verhoeven, Ac" uniqKey="Verhoeven A">AC Verhoeven</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Landewe, R" uniqKey="Landewe R">R Landewe</name></author><author><name sortKey="Van Der Heijde, D" uniqKey="Van Der Heijde D">D van der Heijde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharp, Jt" uniqKey="Sharp J">JT Sharp</name></author><author><name sortKey="Wolfe, F" uniqKey="Wolfe F">F Wolfe</name></author><author><name sortKey="Lassere, M" uniqKey="Lassere M">M Lassere</name></author><author><name sortKey="Boers, M" uniqKey="Boers M">M Boers</name></author><author><name sortKey="Van Der Heijde, D" uniqKey="Van Der Heijde D">D Van Der Heijde</name></author><author><name sortKey="Larsen, A" uniqKey="Larsen A">A Larsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="St Clair, Ew" uniqKey="St Clair E">EW St Clair</name></author><author><name sortKey="Van Der Heijde, Dm" uniqKey="Van Der Heijde D">DM van der Heijde</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Maini, Rn" uniqKey="Maini R">RN Maini</name></author><author><name sortKey="Bathon, Jm" uniqKey="Bathon J">JM Bathon</name></author><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bathon, Jm" uniqKey="Bathon J">JM Bathon</name></author><author><name sortKey="Martin, Rw" uniqKey="Martin R">RW Martin</name></author><author><name sortKey="Fleischmann, Rm" uniqKey="Fleischmann R">RM Fleischmann</name></author><author><name sortKey="Tesser, Jr" uniqKey="Tesser J">JR Tesser</name></author><author><name sortKey="Schiff, Mh" uniqKey="Schiff M">MH Schiff</name></author><author><name sortKey="Keystone, Ec" uniqKey="Keystone E">EC Keystone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Breedveld, Fc" uniqKey="Breedveld F">FC Breedveld</name></author><author><name sortKey="Weisman, Mh" uniqKey="Weisman M">MH Weisman</name></author><author><name sortKey="Kavanaugh, Af" uniqKey="Kavanaugh A">AF Kavanaugh</name></author><author><name sortKey="Cohen, Sb" uniqKey="Cohen S">SB Cohen</name></author><author><name sortKey="Pavelka, K" uniqKey="Pavelka K">K Pavelka</name></author><author><name sortKey="Van Vollenhoven, R" uniqKey="Van Vollenhoven R">R van Vollenhoven</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klareskog, L" uniqKey="Klareskog L">L Klareskog</name></author><author><name sortKey="Van Der Heijde, D" uniqKey="Van Der Heijde D">D van der Heijde</name></author><author><name sortKey="De Jager, Jp" uniqKey="De Jager J">JP de Jager</name></author><author><name sortKey="Gough, A" uniqKey="Gough A">A Gough</name></author><author><name sortKey="Kalden, J" uniqKey="Kalden J">J Kalden</name></author><author><name sortKey="Malaise, M" uniqKey="Malaise M">M Malaise</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cohen, Sb" uniqKey="Cohen S">SB Cohen</name></author><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author><author><name sortKey="Greenwald, Mw" uniqKey="Greenwald M">MW Greenwald</name></author><author><name sortKey="Dougados, M" uniqKey="Dougados M">M Dougados</name></author><author><name sortKey="Furie, Ra" uniqKey="Furie R">RA Furie</name></author><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genant, Hk" uniqKey="Genant H">HK Genant</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title-group><journal-title>Annals of the Rheumatic Diseases</journal-title></journal-title-group><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18086727</article-id><article-id pub-id-type="pmc">2569144</article-id><article-id pub-id-type="publisher-id">ar85084</article-id><article-id pub-id-type="doi">10.1136/ard.2007.085084</article-id><article-categories><subj-group subj-group-type="heading"><subject>Extended Reports</subject></subj-group></article-categories><title-group><article-title>Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial</article-title><alt-title alt-title-type="running-head">Extended report</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Genant</surname><given-names>H K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Peterfy</surname><given-names>C G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Westhovens</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Becker</surname><given-names>J-C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Aranda</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Vratsanos</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Teng</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kremer</surname><given-names>J M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>University of California, San Francisco, San Francisco, California, USA</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Synarc, Inc., San Francisco, California, USA</addr-line></aff><aff id="aff3"><label>3</label><addr-line>UZ Gasthuisberg, Leuven, Belgium</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Global Clinical Research, Immunology, Bristol-Myers Squibb, Princeton, New Jersey, USA</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Albany Medical College and The Center for Rheumatology, Albany, New York, USA</addr-line></aff><author-notes><corresp>Correspondence to: Harry K Genant, University of California, San Francisco, San Francisco, CA, USA; <email>harry.genant@ucsf.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2007</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>11</month><year>2007</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on the
<volume>67</volume><issue>8</issue><fpage>1084</fpage><lpage>1089</lpage><history><date date-type="accepted"><day>17</day><month>11</month><year>2007</year></date></history><permissions><copyright-statement>© Genant et al 2008</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective:</title><p>Assess the effect of abatacept on progression of structural damage over 2 years in patients with rheumatoid arthritis who had an inadequate response to methotrexate.</p></sec><sec><title>Methods:</title><p>539 patients entered an open-label extension of the AIM (<underline>A</underline>batacept in <underline>I</underline>nadequate responders to <underline>M</underline>ethotrexate) trial and received abatacept. Radiographic assessment of the hands and feet was performed at baseline, year 1 and year 2. At year 2, each patient’s radiographs were scored for progression blinded to sequence and treatment allocation.</p></sec><sec><title>Results:</title><p>In patients treated with abatacept for 2 years, greater reduction in progression of structural damage was observed in year 2 than in year 1. The mean change in total Genant-modified Sharp scores was reduced from 1.07 units in year 1 to 0.46 units in year 2. Similar reductions were observed in erosion and joint space narrowing scores. Following 2 years of treatment with abatacept, 50% of patients had no progression of structural damage as defined by a change in the total score of ⩽0 compared with baseline. 56% of patients treated with abatacept had no progression during the first year compared with 45% of patients treated with placebo. In their second year of treatment with abatacept, more patients had no progression than in the first year (66% vs 56%).</p></sec><sec><title>Conclusions:</title><p>Abatacept has a sustained effect that inhibits progression of structural damage. Furthermore, the mean change in radiographic progression in patients treated with abatacept for 2 years was significantly lower in year 2 versus year 1, suggesting that abatacept may have an increasing disease-modifying effect on structural damage over time.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000318 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000318 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:2569144
|texte= Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:18086727" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a OpenAccessBelV2
| This area was generated with Dilib version V0.6.25. |  |